|
BR112017008672A2
|
|
improved il-6 antibodies
|
|
WO2016073894A1
|
|
Therapeutic agents with increased ocular retention
|
|
WO2015200438A1
|
|
High affinity antibodies against pcsk9
|
|
WO2015138844A1
|
|
Methods for production of stable chimeric cytokine protein formulations in blow fill seal containers
|
|
WO2015048526A1
|
|
Treating ocular pain
|
|
WO2014179657A1
|
|
Albumin variants binding to fcrn
|
|
CN107693781A
|
|
Chimeric cell factor formulations for ocular delivery
|
|
WO2014107739A1
|
|
Antibodies against pcsk9
|
|
WO2014107737A2
|
|
Local delivery of il-17 inhibitors for treating ocular disease
|
|
WO2014089267A1
|
|
Galectin-3 fusion proteins
|
|
WO2014074905A1
|
|
Il-6 antagonists and uses thereof
|
|
US2014315817A1
|
|
Variant serum albumin with improved half-life and other properties
|
|
CA2843197A1
|
|
Purified proteins
|
|
WO2012103240A2
|
|
Chimeric il-1 receptor type i agonists and antagonists
|
|
BR112013003646A2
|
|
chimeric il-1 type I receptor antagonists and agonists.
|
|
TW201217528A
|
|
Chimeric il-1 receptor type i antagonists
|
|
WO2011163452A2
|
|
Treating surface of the eye disorders
|
